Mіcro- and mаcrovascular complications in a patient with type 2 diabetes mellitus: a case report

Saienko Y.A.,
Ukrainian Cardiac Center, Kyiv, Ukraine; D. F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of Ukraine;

Marushko Y.U.,
Ukrainian Cardiac Center, Kyiv, Ukraine;

Zubovych I.V.,
Ukrainian Cardiac Center, Kyiv, Ukraine;

Mankovsky B.M.,
Ukrainian Cardiac Center, Kyiv, Ukraine; D. F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of Ukraine;

Key words: diabetes mellitus, myocardial infarction, chronic kidney disease, diabetic retinopathy, diabetic polyneuropathy


Late detection and prolonged decompensation of diabetes mellitus lead to the development of severe vascular complications. These include microvascular complications such as retinopathy and nephropathy, and macrovascular complications such as myocardial infarction, stroke, peripheral artery disease, as well as diabetic neuropathy. The presented clinical case clearly demonstrates the connection between the untimely diagnosis of diabetes mellitus and the development of severe, irreversible consequences.

It is known that diabetes mellitus leads to damage to target organs: eyes, kidneys, heart, as well as blood vessels and nerve endings. We decided to describe a clinical case of a man who developed typical complications of diabetes mellitus and to show a comprehensive approach to the treatment of a comorbid patient. The prescription of modern therapy according to global recommendations delays the development of complications, but unfortunately, the late diagnosis of diabetes in this patient led to irreversible consequences.


It should be remembered that adherence to a nutritional regimen, strict control of glycemia, blood pressure, cholesterol levels, and physical activity can reduce the development of micro- and macrovascular complications in people with type 2 diabetes mellitus. 

1. P. Theofilis et al. Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors. Life. 2023. Vol. 13, no. 2. P. 497. URL: https://doi.org/10.3390/life13020497

2. Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition committee. IDF Diabetes Atlas [Internet]. 10th ed. Brussels: International Diabetes Federation; 2023. https://doi. org/10.1016/j.diabres.2021.109119

3. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al.; American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl1):S19-S40. https://doi.org/10.2337/dc23-S002

4. American Diabetes Association. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes—2022. Diabetes Care. 2022;45, S113-s124.

5. American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes—2024. Diabetes Care. 2024;45, S144-s174.

6. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Nephrology and Dialysis. 2023. Vol. 25, no. 2. P. 141221. URL: https://doi. org/10.28996/2618-9801-2023-2-141-221

7. Kaplinsky E. DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. Drugs Context. 2020;9:2019-11-3. https://doi. org/10.7573/dic.2019-11-3

8. Pei J, Wang X, Xing Z, Zheng K, Hu X. Short-term and long- term outcomes of revascularization interventions for patients with severely reduced left ventricular ejection fraction: a meta-analysis. ESC Heart Fail. 2021;8(1):634-643. https:// doi.org/10.1002/ehf2.13141

9. Theresa A McDonagh, Marco Metra, Marianna Adamo, Roy S Gardner, Andreas Baumbach, Michael Böhm, Haran Burri, Javed Butler, Jelena Čelutkienė, Ovidiu Chioncel, John G F Cleland, Maria Generosa Crespo-Leiro, Dimitrios Farmakis, Martine Gilard, Stephane Heymans, Arno W Hoes, Tiny Jaarsma, Ewa A Jankowska, Mitja Lainscak, Carolyn S P Lam, Alexander R Lyon, John J V McMurray, Alexandre Mebazaa, Richard Mindham, Claudio Muneretto, Massimo Francesco Piepoli, Susanna Price, Giuseppe M C Rosano, Frank Ruschitzka Focused Update of the 2021 ESC Guide- lines for the diagnosis and treatment of acute and chronic heart failure ESC Clinical Practice Guidelines, 25 Aug 2023 10.1093/eurheartj/ehad195

10. Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al.; EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. J Am Coll Cardiol. 2021;77(11):1381-1392. https://doi.org/10.1016/j. jacc.2021.01.033

11. Oyama K, Raz I, Cahn A, Goodrich E, Bhatt D, Leiter L, et al. Influence of cardiovascular drugs on the efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial [abstract]. Eur Heart J. 2021;42 Suppl 1:ehab724.2961. https://doi.org/10.1093/ eurheartj/ehab724.2961


12. Hyts AR. [The latest therapeutic opportunities in the treatment of chronic heart failure]. Ukrainskyi medychnyi chasopys. 2021;(4):1-6. Ukrainian. https://doi.org/10.32471/ umj.1680-3051.144.214325 


How to Cite

Saienko Y.A., Marushko Y.U., Zubovych I.V., Mankovsky B.M. (2024). Mіcro- and mаcrovascular complications in a patient with type 2 diabetes mellitus: a case report. Diabetes Obesity Metabolic Syndrome. 13(3), 34-39. https://doi.org/10.57105/2415-7252-2024-3-02